跳至主要内容
临床试验/NCT00861900
NCT00861900已完成不适用

Immune Mechanisms of Rejection in Human Lung Allografts

Washington University School of Medicine0 个研究点目标入组 778 人开始时间: 1998年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
778
主要终点
The primary efficacy event is the change in pulmonary function testing values (FEV1).

研究概览

简要总结

The investigators have obtained compelling evidence that the development of anti-human leukocyte antigen (anti-HLA) antibodies against mismatched donor antigens significantly correlates with the development of bronchiolitis obliterans (BOS). Further, these anti-HLA antibodies are developed at least 15 months prior to any clinical evidence of BOS. This lag period between the development of anti-HLA antibodies and the onset of BOS gives us an opportunity to intervene to delay and/or prevent the development of BOS.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Lung transplant recipient.

排除标准

  • Pregnant women,
  • Prisoners, AND
  • Anyone who is unable or unwilling to consent to this study.

结局指标

主要结局

The primary efficacy event is the change in pulmonary function testing values (FEV1).

时间窗: Lung function is monitored at regular intervals. Patients will be followed for five years.

次要结局

  • Secondary efficacy measurements include allograft and patient survival, incidence of BOS and Obliterative bronchiolitis.(The subjects are monitored at regular intervals. Patients will be followed for five years.)

研究者

申办方类型
Other
责任方
Sponsor

相似试验